IP Library Granted Patent US 10,765,500
Granted Patent B2
US 10,765,500 · App. 15/975,273 · Granted Sep 8, 2020

Temporarily stiffened mesh prostheses

Inventors: Fatima Buevich (Highland Park, NJ); Frank Do (Jersey City, NJ); William McJames (Hillsborough, NJ); Satish Pulapura (Monmouth Junction, NJ); William Edelman (Sharon, MA); Arikha Moses (New York, NY); Mason Diamond (Wayne, NJ); Shari Timothy (North Brunswick, NJ)
Assignee: MEDTRONIC, INC.
A61F2/0063A61L27/34A61L27/54A61L27/56A61L27/58A61L31/10A61L31/146A61L31/148A61L31/16A61F2210/0004A61F2250/0067A61F2310/0097A61L2300/402A61L2300/404A61L2300/406A61L2300/416A61L2300/45A61L2300/606A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,765,500
App. No.
15/975,273
Granted
Sep 8, 2020
Kind
B2
Abstract

The present invention relates to medical prostheses and methods of manufacturing those devices. In particular, the prostheses are temporarily stiffened meshes with particular coatings to provide initial stiffness and thereby permit easier surgical handling for treatment or reconstruction of soft tissue defects. Preferred embodiments include surgical meshes coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and/or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The devices of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use. By including biologically active agents and/or drugs in the coating, the devices provide prophylaxis for and can alleviate side effects or complications associated with the surgery or use of prostheses in general.

Claims (27)

1. A medical prosthesis comprising:

a surgical mesh with a coating, the coating including a first layer and a second layer, the first layer being positioned between the mesh and the second layer,

wherein the coating is applied to the mesh without substantially altering a porosity of the mesh,

wherein the first layer comprises a first polymer and the second layer comprises a second polymer that is different than the first polymer, and

wherein at least one of the polymers comprises a tyrosine-derived polyarylate.

2. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and the first polymer is hydrophilic and comprises a water soluble drug.

3. A medical prosthesis comprising:

a surgical mesh with a coating, the coating including a first layer and a second layer, the first layer being positioned between the mesh and the second layer, the first layer comprising a water soluble polymer, the second layer comprising a non-water soluble polymer,

wherein the coating is applied to the mesh without substantially altering a porosity of the mesh,

wherein the first layer comprises a water soluble drug that is dissolved in the water soluble polymer, and

wherein the non-water soluble polymer comprises a tyrosine-derived polyarylate.

4. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and the first polymer is hydrophilic and comprises chitosan.

5. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and chitosan and the first polymer is hydrophilic and comprises chitosan.

6. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and cellulose and the first polymer is hydrophilic and comprises chitosan.

7. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and a mixture of rifampin and minocycline and the first polymer is hydrophilic and comprises chitosan.

8. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and the first polymer comprises PEG and chitosan.

9. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and chitosan and the first polymer comprises PEG and chitosan.

10. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and cellulose and the first polymer comprises PEG and chitosan.

11. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and a mixture of rifampin and minocycline and the first polymer comprises PEG and chitosan.

12. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and the first polymer comprises collagen and chitosan.

13. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and chitosan and the first polymer comprises collagen and chitosan.

14. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and cellulose and the first polymer comprises collagen and chitosan.

15. A medical prosthesis as recited in claim 1 , wherein the second polymer comprises the tyrosine-derived polyarylate and a mixture of rifampin and minocycline and the first polymer comprises collagen and chitosan.

16. A medical prosthesis comprising:

a surgical mesh with a coating, the coating including a first layer and a second layer, the first layer being positioned between the mesh and the second layer, wherein the coating is applied to the mesh without substantially altering a porosity of the mesh,

wherein the first layer comprises a first polymer and the second layer comprises a second polymer that is different than the first polymer, and

wherein at least one of the polymers comprises a tyrosine-derived polyarylate and a mixture of rifampin and minocycline.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Feb 10, 2020
From: TYRX, INC.; MEDTRONIC, INC.
To: MEDTRONIC, INC.
Reel/Frame 051770/0976 →
CHANGE OF NAME Recorded May 9, 2018
From: TYRX PHARMA
To: TYRX, INC.
Reel/Frame 045756/0089 →
MERGER AND CHANGE OF NAME Recorded May 9, 2018
From: MEDTRONIC TRECKS, INC.; TYRX, INC.
To: TYRX, INC.
Reel/Frame 045756/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2018
From: BUEVICH, FATIMA; DO, FRANK; MCJAMES, WILLIAM; PULAPURA, SATISH; EDELMAN, WILLIAM; MOSES, ARIKHA; DIAMOND, MASON; TIMOTHY, SHARI
To: TYRX PHARMA, INC.
Reel/Frame 045756/0270 →
Cited By (1)
US 12,582,767